Capan-1 Cells

The Capan-1 cell line is derived from a human pancreatic adenocarcinoma and was established from the ascitic fluid of a 40-year-old Caucasian male. It was first characterized in 1975 and is particularly noted for its ductal epithelial morphology, which closely resembles that of primary pancreatic tumors. Capan-1 cells are extensively used in research aimed at understanding pancreatic cancer biology, including studies on tumor progression, metastasis, and treatment resistance. This cell line is well-regarded for its ability to produce mucin, a characteristic feature of many pancreatic adenocarcinomas, thus serving as a model for mucinous pancreatic cancer. Genetically, Capan-1 harbors mutations in the KRAS gene, which are typical of pancreatic cancer, as well as alterations in other cancer-related genes such as TP53 and SMAD4. These mutations make the Capan-1 cell line a valuable tool for studying the molecular mechanisms underlying pancreatic cancer and for the preclinical evaluation of new therapeutic agents targeting these pathways. Furthermore, Capan-1 cells are used to study the biology of pancreatic cancer stem cells, offering insights into the behaviors that drive cancer recurrence and resistance to conventional therapies. Pancreas cancer cell lines, Pancreas, Ductal adenocarcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1